EQS-News

Sino Biological Launches XPressMAX(TM) Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery 18.05.2026, 17:57 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Sino Biological / Key word(s): Financial
Sino Biological Launches XPressMAX(TM) Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

18.05.2026 / 17:57 CET/CEST
The issuer is solely responsible for the content of this announcement.


Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening

HOUSTON, TEXAS - May 18, 2026 (NEWMEDIAWIRE) - Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, is proud to announce the launch of its innovative XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02) , a cutting-edge solution designed to supercharge artificial intelligence (AI)-driven high-throughput screening pipelines for antibody drug discovery. 

XPressMAX™ Cell-Free Protein Synthesis Kit

The novel kit leverages advanced cell-free protein synthesis technology to enable rapid, efficient in vitro production of target proteins and antibodies - eliminating the constraints of traditional cell-based expression systems. By seamlessly integrating with AI-powered screening platforms, the new offering empowers researchers to dramatically accelerate the identification and optimization of promising antibody candidates, reducing both development timelines and costs.

Based on an E. coli lysate and fully supplemented with essential transcription and translation components, XPressMAX™ enables direct protein synthesis from plasmid or PCR templates. Specifically designed for antibody drug discovery, XPressMAX™ enables rapid expression and validation of VHH, scFv, Fab, and Miniprotein. Leveraging XPressMAX™, Sino Biological has established a high-throughput cell-free expression platform that validates 2,000+ scFv/VHH molecules in 3-4 weeks to match AI’s rapid iteration.

XPressMAX™ Highlights

  • Ultra-Fast Synthesis: Synthesis completed in just 3 hours
  • High Success Rate: Greater than 99%, reliable system performance.
  • Supports Complex Disulfide Bonding: Native folding and bioactivity without additional enhancers.

"Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. "By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality."

"AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput," said Dr. Jie Zhang, Sino Biological’s General Manager. "XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours."

Researchers can visit www.sinobiological.com to explore more about XPressMAX™ or click here to request a free sample.

About Sino Biological

Sino Biological is an international reagent supplier and CRO service provider specializing in recombinant protein production and antibody development. With the US-based Center for Bioprocessing (C4B) in Houston and SignalChem Biotech (part of Sino Biological) in Canada, Sino Biological delivers tailored, localized solutions to meet diverse research needs worldwide. Serving researchers in over 90 countries, the company maintains a stringent quality management system across all products.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on Sino Biological management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which Sino Biological has no control. Sino Biological assumes no obligation to update these forward-looking statements and does not intend to do so.

For media inquiries or partnership opportunities, please contact:

Sino Biological, Inc.
gmo@sinobiological.cn
www.sinobiological.com

View the original release on www.newmediawire.com


News Source: Sino Biological


18.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Sino Biological
United States
ISIN: CNE100004Q23
EQS News ID: 2329390

 
End of News EQS News Service

2329390  18.05.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer